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Abstract  45 
Hypertension is a leading risk factor for death and dependency after ischaemic stroke. However, 46 
administering anti-hypertensive medications post-stroke remains contentious with concerns 47 
regarding deleterious effects on cerebral blood flow and infarct expansion. This study sought to 48 
determine the effect of glyceryl trinitrate (GTN) treatment in both lissencephalic and gyrencephalic 49 
pre-clinical stroke models.  50 
Merino sheep underwent middle cerebral artery occlusion (MCAO) followed by GTN or control 51 
patch administration (0.2mg/h). Monitoring of numerous physiologically relevant measures over 52 
24h showed that GTN administration was associated with decreased intracranial pressure, infarct 53 
volume, cerebral oedema and midline shift compared to vehicle treatment (p<0.05). No significant 54 
changes in blood pressure or cerebral perfusion pressure were observed. 55 
Using optical imaging spectroscopy and laser speckle imaging, the effect of varying doses of GTN 56 
(0.69-50µg/h) on cerebral blood flow and tissue oxygenation was examined in mice.  No 57 
consistent effect was found. Additional mice undergoing MCAO followed by GTN administration 58 
(doses varying from 0-60µg/h) also showed no improvement in infarct volume or neurological 59 
score within 24h post-stroke.  60 
GTN administration significantly improved numerous stroke-related physiological outcomes in 61 
sheep but was ineffective in mice. This suggests that, whilst GTN administration could potentially 62 
benefit patients, further research into mechanisms of action are required. 63 
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Glyceryl trinitrate (GTN) is an organic nitric oxide (NO) donor widely used for the treatment of 68 
angina, myocardial infarction and heart congestion.1 NO metabolites are potent vasodilators via 69 
actions on smooth muscle cells, and GTN reduces blood pressure due to increased arterial 70 
compliance and decreased venous return.2 Treatment is easy to administer via transdermal 71 
patches, exhibits a moderate half-life, and has a low risk of serious side effects. GTN is therefore 72 
an attractive drug to re-purpose for the acute treatment of ischemic stroke. Preliminary evidence 73 
from a small ambulance-based trial (Rapid Intervention with Glyceryl trinitrate in Hypertensive 74 
stroke Trial (RIGHT)) found that transdermal administration of GTN to probable stroke patients 75 
significantly lowered blood pressure (~18mmHg) within 2h of patch administration.3 GTN also 76 
improved functional outcome at 90 days. The subsequent large multi-centre Efficacy of Nitric 77 
Oxide in Stroke (ENOS) trial that administered GTN within 48hrs of symptom onset for 7 days 78 
failed to observe functional benefit at 90 days.4 However, a prospective analysis of a sub-group 79 
of ENOS patients treated within 6h of stroke onset suggested that GTN improved functional 80 
outcome.5 The multi-centre ambulance-based RIGHT-2 trial was therefore designed to determine 81 
whether early (<4h), ambulance based administration of GTN could improve functional outcome, 82 
but the results were surprisingly neutral, possibly because treatment was started too early.6 83 
Successful re-purposing of GTN may require greater understanding of the risks and benefits of 84 
anti-hypertensive treatment in the acute stroke setting, as reviewed by Appleton et al.7 If mean 85 
arterial blood pressure (MABP) decreases, cerebral perfusion pressure (CPP) and cerebral blood 86 
flow (CBF) may also decrease. Therefore, aggressive reductions in blood pressure at the time of 87 
stroke may compromise collateral blood flow.8 On the other hand, hypertension is an independent 88 
risk factor for death and dependency at 6 months post-stroke,9 and can contribute to dangerous 89 




vasodilatory capacity, it did not reduce CBF or CPP in stroke patients.10 This may be because the 91 
cerebral vessels are already maximally dilated, but if this was the case, it is expected that ICP 92 
would be increased. Measuring ICP in patients is difficult due to the requirement of intracranial 93 
probes. As such, we have developed a method to measure ICP in an ovine model of stroke.11–15 94 
We sought to measure ICP, MABP, and CPP in the ovine stroke model following a clinically 95 
relevant, transdermal dose of GTN.  96 
Rodent models also offer the opportunity to obtain further insight into the pleiotropic mechanisms 97 
by which GTN may or may not offer benefit in stroke. For example, a single intra-peritoneal, or 98 
intra-arterial, dose of GTN has been reported to reduce neuronal death and infarct volume when 99 
given before or near to the time of transient middle cerebral artery occlusion (MCAO) in rats16 and 100 
mice.17 Additionally, there was evidence of decreased production of the anti-apoptotic factor Bcl-101 
2 as a result of GTN administration.16  GTN did not influence cerebral perfusion, implying 102 
additional mechanisms. The dosing regimens in both studies, however, were quite high compared 103 
to the clinical scenario. Therefore, we sought to establish a dose response for a more prolonged 104 
dose of GTN in a mouse model of MCAO. This was combined with measures of CBF and brain 105 




Materials and Methods 107 
Ethical approval: All applicable institutional and national guidelines for the care and use of 108 
animals were followed, and all procedures were performed in accordance with local laws. Ovine 109 
experiments were approved by the Animal Ethics Committee of South Australian Health and 110 
Medical Research Institute (SAHMRI; SAM238) and conducted according to guidelines 111 
established for the use of animals in experimental research as outlined by the Australian National 112 
Health and Medical Research Council code of practice for the care and use of animals for 113 
scientific purposes (8th edition, 2013). All rodent experiments were performed in accordance with 114 
the Animal (Scientific Procedures) Act, 1986, under licences approved by the UK home office. 115 
Studies are reported in accordance with the ARRIVE guidelines.  116 
Ovine studies 117 
Animals and GTN Administration 118 
Purebred female Merino sheep (Ovis aries, n=18) aged 18–24 months and weighing 60.71 ± 5.58 119 
kg were sourced from a single property in Penneshaw, South Australia. Animals were transported 120 
to the SAHMRI Large Animal Research and Imaging Facility (LARIF) in South Australia, where 121 
all experimental procedures were carried out. Statistical power calculations were performed 122 
(GPower v 3.1) to determine the required sample size to reach a power of 80%, alpha 0.05, and 123 
an effect size of 0.85 (based on findings from previous studies14), with the minimum number of 124 
animals required n=7/group. Historical sham (n=4) and stroke with no treatment (n=7) data was 125 
used in this study. An additional group received subdermal GTN (n=7; Nitro-Dur 0.2mg/h, Merck 126 
Sharp & Dohme Ltd, UK), applied at 1h following MCAO and left in place for the duration of the 127 
experiment. The GTN dose administered was equivalent to human trials.6 Unfortunately, male 128 




convoluted male urethra, as urinary catheterisation is a physiological necessity with the prolonged 130 
general anaesthesia (>24-hour) in our experiment. An individual trained surgeon carried out all 131 
intracranial procedures, and as such, surgery and treatment processes were unable to be blinded. 132 
However, all analyses were conducted in a blinded fashion, including calculation of ICP, oedema, 133 
midline shift, physiological variables, MABP and infarct volume. Exclusion criterion included 134 
premature death and iatrogenic injury (e.g. significant bleeding or cerebral contusion) during the 135 
MCAO surgery.  136 
 137 
Anaesthesia, Blood Pressure and Intracranial Pressure Monitoring 138 
Anaesthesia was induced with a combination of intravenous ketamine (100mg/kg, CEVA, 139 
Australia) and diazepam (5mg/ml, Pamlin, CEVA, Australia). Animals were intubated and 140 
anaesthesia maintained via intravenous ketamine infusion (4mg/kg/h, Parnell Australia Pty Ltd)  141 
in combination with 1.5-2% isoflurane (Veterinary companies of Australia Pty Ltd).18,19 with 142 
medical air or 100% oxygen. An arterial femoral catheter continuously monitored blood pressure, 143 
and blood gas samples were acquired at hourly intervals to maintain physiological pO2, pCO2 and 144 
pH. Sodium chloride was used to ensure arterial catheter patency. A femoral venous catheter was 145 
used for ketamine and crystalloid fluid administration (sodium lactate, Baxter Health, Australia).  146 
A burr hole was drilled in the right parietal bone posterior to the coronal suture and approximately 147 
20 mm from the sagittal suture, the dura perforated, and skull bolts secured. A Codman 148 
microsensor ICP probe (Codman & Shurtleff Inc., MA) was inserted into the cerebral parenchyma 149 
(approximately 15 mm in depth) to measure ICP within the supratentorial compartment. LabChart 150 
Reader (v 8.1.1) continuously recorded ICP and MABP throughout the 24h monitoring period. 151 
CPP was calculated by subtracting MABP from ICP. ICP/CPP/MABP data for one animal was 152 




Surgical Approach  154 
Briefly, a 50mm vertical incision was made posterior to the right eye. A small craniotomy was 155 
performed at the junction of the parietal and squamous temporal bones, followed by a 156 
durotomy.11,12 The anterior temporal lobe was gently retracted, and the proximal middle cerebral 157 
artery (MCA) located and dissected. In the permanent MCAO group, the MCA was occluded 158 
proximally via electrocautery with Malis bipolar diathermy forceps (Valleylab Inc., CO). In both 159 
MCAO and sham animals, the brain was irrigated with saline, synthetic dura (Durepair, Medtronic) 160 
interleaved to reinforce the dural matrix, and sealed with ethyl cyanoacrylate (Bostik, Australia) to 161 
reduce cerebrospinal fluid (CSF) leakage. Sham animals underwent all surgical procedures, 162 
including dural opening, CSF aspiration and MCA dissection, with the exception of direct 163 
electrocautery and occlusion of the MCA11. In all animals, a cranioplasty was performed with 164 
dental acrylic cement (Lang Dental, IL) to maintain the shape of the cranial cavity and 165 
homeostasis of ICP dynamics, and the wound closed. The head was returned to a neutral position 166 
for monitoring under general anaesthesia for 24h.  167 
Magnetic Resonance Imaging (MRI) 168 
At 24h MRI was performed under 3% isoflurane on a 3T scanner (Siemens Skyra; Siemens AG, 169 
Munich, Germany). Fluid attenuated inversion recovery (FLAIR), T2 weighted (T2WI), echo planar 170 
(EPI), magnetic resonance angiography (MRA) and diffusion weighted (DWI) images were 171 
acquired. Apparent diffusion coefficient (ADC) maps were automatically calculated using inbuilt 172 
Siemens software (Syngo.via vB10) where a log-linear regression model was used to calculate 173 
the ADC for each voxel acquired in the DWI (ADC reported as 10-3 mm2/s). 174 
The extent of the midline shift was assessed from the T2WI at the level of the septum pellucidum 175 




via computer-aided manual delineation of the hyperintense lesion by a blinded assessor using 177 
Horos DICOM image viewer (v3.1.1). Semi-automated segmentation of DWI data was performed 178 
with ITK-SNAP (v 3.7)20 to estimate infarct volume.  179 
Histological Examination 180 
Following MRI, animals were maintained on inhalational isoflurane, intravenous heparin 181 
(5000I.U./5ml; Pfizer, NY) was administered and animals euthanised via exsanguination and 182 
perfusion with TRIS-buffered saline. The brains were removed and sliced into 10mm coronal 183 
sections and immersed in 3% 2,3,5-Triphenyltetrazolium chloride solution (TTC) (Sigma-Aldrich, 184 
Australia) at 37°C in the dark for 10min. Slices were photographed and lesion volume calculated 185 
as a percentage of the ipsilateral hemisphere and averaged for both posterior and anterior 186 
surfaces using ImageJ (v 1.49) by an individual blinded to the treatment allocation.  187 
Rodent studies 188 
Animals and GTN administration  189 
Seventy-four male C57BL/6 mice (Charles River, UK, approx. 25-30g, 10 – 12 wks. old) were 190 
housed under standard conditions (21-23oC, 12h light-dark cycle) in individually ventilated cages, 191 
with standard bedding and a tube, and fed ad libitum on standard rodent chow.  192 
A GTN dose of 0.84µg/h was calculated (based on body surface area) to be equivalent to 0.2mg/h 193 
in humans.4 Nevertheless, a range of doses were tested. To examine the effect of GTN on CBF, 194 
16 mice were randomized to receive a transdermal patch that was adjusted for size (50µg/h = 195 
1.6cm2, 12.5µg/h = 0.8cm2, 3.12µg/h = 0.4cm2, and 0.69µg/h = 0.2cm2), to compare to baseline 196 
measurements. An additional 12 mice were similarly randomized for tissue oxygenation 197 




effect on cerebral blood flow was evident, and therefore the data is presented with descriptive 199 
statistics only.  200 
As there were limitations with using transdermal patches for recovery experiments, the effect of 201 
GTN on stroke outcome in 46 mice was assessed using pre-primed osmotic mini-pumps (8.0µl/h 202 
for >24h; ALZET, US; model: 2001D), which would deliver GTN for the duration of the study. An 203 
independent investigator used adaptive randomisation (4.1, University of Texas M.D. Anderson 204 
Cancer Centre) based on infarct volume data from the previous day, which assigns more animals 205 
to doses that appear to be effective. Power calculations based on lesion volumes from the same 206 
model produced in our group indicated for a power of 80% and alpha 0.05, to see a 50% reduction 207 
in lesion volume (37.5mm3 to 18.75mm3, 13.7 SD) 8 per group was required. Therefore, 46 mice 208 
entered the adaptive randomisation (with the additional 6 mice being included to account for any 209 
attrition). All experimenters performing surgery, carrying out behaviour and analysing infarct 210 
volume and NOx levels were blind to group allocation. Treatment group was random across time 211 
of day and cage of animal to control for bias. GTN (Hospira, UK, 5mg/ml GTN in 67% ethanol and 212 
4.3% PEG) was diluted further with PEG to deliver the following doses: 0.078, 0.78, 7.8 and 60 213 
µg/h. Due to a limit on the alcohol concentration that could be delivered by the pumps (15%), the 214 
highest dose was prepared from a 5% stock solution (50mg/ml GTN in 70% ethanol (UNIKEM, 215 
Switzerland) donated by Professor Eaton)). Control mice received the vehicle (15% ethanol in 216 
PEG). The pumps were inserted under the skin of the flank 20min after stroke. A priori exclusion 217 
criteria included complications during surgery (failure to advance filament or excessive bleeding) 218 
prior to treatment.  Meeting humane endpoints (for example, 20-30% weight loss, laboured 219 
breathing, or seizures) after treatment, resulted in euthanasia, but maximal scores were included 220 
in analysis of neuroscore and infarct volume (two animals in the 0.078 µg/h group).  Final group 221 





Cerebral blood flow and oxygenation measurements 224 
Mice underwent CBF measurements with laser speckle flow imaging (moorFLPI-2, Moor 225 
Instruments, UK). Animals were anaesthetised with isoflurane anaesthesia in room air and 226 
artificially ventilated (Zoovent Jetsys ventilator, Universal Lung Ventilators Ltd, Milton Keynes, 227 
UK). Animals were fixed in a stereotactic frame (Narishige, Tokyo, Japan) and body temperature 228 
maintained at 36.9 ± 0.2°C via a heating blanket controlled with a rectal probe (Harvard 229 
Apparatus, Kent, UK). Heart rate was monitored via ECG throughout the experiment. A midline 230 
incision in the scalp was made and the skull exposed. CBF was recorded at baseline (timepoint 231 
1), during (timepoint 2), and after (timepoint 3) the application of GTN via the transdermal patches. 232 
Data from one mouse was of insufficient quality to include in analysis (0.69µg/h group).  233 
Two-dimensional optical imaging spectroscopy (Abbott, Berkshire, UK) was performed to 234 
measure tissue oxygenation. Animals were prepared as per above, and then a soft paraffin 235 
(Vaseline) well was constructed over the left somatosensory cortex and filled with 37°C saline. 236 
The well was sealed with a glass coverslip to create a stable imaging window.21 Imaging data 237 
were collected using a high signal to noise charged coupled device (CCD) camera (Pantera 1M30, 238 
DALSA, Munich, Germany). The region of interest was illuminated sequentially by four different 239 
wavelengths of light (550 ± 10, 560 ± 10, 577 ± 10, and 700 ± 10 nm) using a Lambda DG-4 high-240 
speed filter changer (Sutter Instruments, Novato, CA, USA). Camera data collection was 241 
synchronised with the filter changer so that each image frame was recorded with one of the four 242 
wavelengths in a sequential manner at a rate of 28 Hz. A modified Beer Lambert law was used 243 




(baseline, 30 and 60min after patch administration, and 30 and 60min after patch removal), 4 data 245 
points could not be obtained (30 and 60min at 0.69 and 12.5 µg/h).  246 
Transient MCAO 247 
Briefly, animals were anaesthetised using isoflurane and a silicone coated nylon filament 248 
(diameter: 0.19mm, Doccol, US) was advanced up the right common carotid artery and secured.22 249 
20min after occlusion preloaded minipumps (see above) were inserted under the skin of the flank. 250 
The filament was removed after 30min, the common carotid was ligated and the wounds sutured. 251 
Body temperature was maintained with a homoeothermic blanket system (Harvard Apparatus, 252 
Kent, UK) and mice received subcutaneous saline. A line block of Ropivacaine Hydrochloride 253 
(2mg/kg; AstraZeneca, UK) was carried out at both surgical sites prior to surgery, and on two 254 
further occasions at 8h intervals. Moist diet was provided the day before and after surgery, 255 
animals were monitored at least hourly once recovered from anaesthesia, until deemed well 256 
enough to be left overnight, then at least 4 times per 24hrs.  257 
Neurological score 258 
At 24h following MCAO, neurological deficits were determined using the Extended Neurological 259 
Score (general and focal) as described previously.23–25 Prematurely euthanised animals were 260 
given maximum neuroscore values and included in the analysis. 261 
Histological examination 262 
Mice from the MCAO study were euthanised using an intraperitoneal injection of Euthatal (0.1mL; 263 
200mg/mL, Merial Animal Health Ltd, UK). A blood sample was taken by cardiac puncture into 264 
tubes coated in K3 EDTA (1.3mL; Greiner Bio-one, UK) and the brain was removed. The 265 




stained with 2% TTC (>95%; Sigma, US), to assess infarct volume. Sections were photographed 267 
with a camera (DS3100; Nikon, UK). Measurements of the infarcted and intact hemispheres were 268 
determined using ImageJ (v 1.49) and non-direct lesion volume was obtained to correct for 269 
oedema.26 Prematurely euthanised animals were given maximum infarct volumes (110mm3) and 270 
included in the analysis.  271 
Nitrate / Nitrite (NOx) analysis  272 
Cerebellar tissue was homogenised in a lysis buffer (20mM Tris and 10mM EDTA, 1mL to 100mg 273 
of tissue) and spun at 3800 x g in a cooled centrifuge for 20min. The supernatant was collected 274 
and 5µL of nitrate reductase and 5µl of co-factor (Nitrite/Nitrate Assay Kit Sigma-Aldrich, UK) was 275 
added to a 40µL sample and incubated for 2h at 25oC to reduce nitrate to nitrite and then to NO 276 
by acetic acid. The same process was repeated for the blood plasma. NO concentration was 277 
quantified using the Sievers Nitric Oxide Analyser (NOA 280i; GE Instruments, UK). Prematurely 278 
euthanised animals were not used in this analysis and 3 plasma and 2 brain samples were not of 279 
sufficient quality to obtain a reading. 280 
Statistical analysis 281 
All data are expressed as mean ± SD, the experimental unit is an individual animal, and analysis 282 
was carried out in GraphPad prism (v 8.0.1). Data was tested for normality using the Shapiro-Wilk 283 
normality test, or by assessing Q-Q plots of residuals. A p-value <0.05 was considered significant 284 
throughout. The primary outcome for both ovine and murine studies was infarct volume.  285 
In the ovine studies, physiological data (pH, pO2, pCO2) were averaged for each treatment group 286 
across all time points and analysed using one-way analysis of variance (ANOVA) followed by 287 
Tukey’s multiple comparison test. MABP and ICP data underwent a logarithmic exponential 288 




followed by Tukey’s post-hoc multiple comparison test. MRI infarct volumes, cerebral oedema, 290 
and midline shift were analysed by t-test. TTC infarct volume was analysed by Mann-Whitney U 291 
test. Linear regression analyses were run to assess the relationship between cerebral oedema, 292 
midline shift and ICP, where an r value >0.5 was considered significant. In the rodent model, NOx 293 
levels were analysed via one-way ANOVA. Infarct volume and neuroscore were analysed via 294 
Kruskal-Wallis. 295 
Results 296 
Ovine Studies  297 
GTN significantly lowers intracranial pressure without affecting cerebral perfusion pressure 298 
All experimental procedures were carried out without complication. There was no statistically 299 
significant difference in pCO2 (F 2, 15 =3.521, p=0.055) or pH (F 2, 15 =0.410, p=0.67) between any 300 
of the groups (Supplemental Table 1). There was however a significant increase in pO2 301 
(Interaction: F 2, 15 =29.78, p<0.0001) in GTN treated animals (pO2 602±21mmHg) when 302 
compared to sham (p<0.0001; pO2 113±14mmHg) and vehicle (p<0.0001; pO2192±186mmHg). 303 
MABP remained within normal physiological limits in sham animals throughout the course of the 304 
experiment (Interaction F 8, 56 =0.098, p=0.999), but was significantly elevated in vehicle treated 305 
animals following stroke at 9 (p=0.038), 14 (p=0.011) and 19h (p=0.028) compared to sham. In 306 
GTN treated animals, however, there was no significant difference in blood pressure when 307 
compared to vehicle or sham at any of the time points (p>0.05) (Fig1A). 308 
At 24h post-stoke, GTN prevented a rise in ICP seen in vehicle treated animals, maintaining 309 
pressure comparable to sham (Fig. 1B; Interaction F 8, 56 =2.371, p=0.028). There was no 310 




9h, however, the vehicle treated MCAO group exhibited significantly higher ICP compared to 312 
shams (p=0.036) and GTN treated animals (p=0.019). ICP continued to rise in vehicle treated 313 
stroke animals at 14h (cf. sham, p=0.033; cf. GTN, p=0.034), 19h (cf. GTN, p=0.05) and 24h (cf.  314 
sham, p=0.002; cf. GTN, p=0.006) (Fig1B). ICP remained within normal physiological limits across 315 
all time points in both sham and GTN treated MCAO animals. CPP, however, was unchanged in 316 
any of the groups at any timepoint (Fig1C; Interaction F 8, 56 =0.412, p=0.901). 317 
GTN reduces infarct volume and cerebral oedema  318 
MRI was unremarkable in sham animals with no evidence of infarction or midline shift (Fig2). All 319 
stroke animals exhibited hyperintensities on DWI and reduced ADC values within the MCA 320 
territory at 24h. There was also strong hyperintensity observed in the same region with T2-321 
weighted images.  322 
On MRI, infarct volume was reduced in GTN compared to vehicle treated animals (GTN 323 
19.32±9.51 cf. vehicle 36.13±17.02; t12 =2.80, p=0.042, effect size (Cohen) = 0.99±0.08-2.36) 324 
(Fig3A). The same reduction was also observed for cerebral oedema (t12 =3.362, p=0.0057) 325 
(Fig3B). Midline shift was present in all stroke animals. However, the extent was markedly 326 
reduced in GTN animals compared to vehicle (t12 =2.920, p=0.013) (Fig3C). Infarct volume from 327 
TTC stained brain slices was also significantly reduced following GTN treatment when compared 328 
to vehicle (GTN 24.81±12.58 cf. vehicle 46.23±18.08; U =6, p=0.018, figure 1 supplement). There 329 
was a strong positive correlation between infarct volume and cerebral oedema (Fig3D, r=0.749, 330 
p<0.001), and cerebral oedema and midline shift (Fig3E, r=0.629, p<0.001). There was also a 331 
positive relationship between ICP and cerebral oedema (Fig3F, r=0.468, p<0.01). 332 
 333 




GTN does not affect cerebral blood flow or tissue oxygenation 335 
Changes in CBF were observed following all GTN doses (Fig4A). However, there was a high 336 
variability between subjects – some exhibited reductions and others increases in CBF. Even after 337 
the patch had been removed for 1h, CBF did not consistently return to baseline. 338 
The HbO2 concentration at baseline was stable, but there was a large variation in values after 339 
GTN application. Each individual took up to 1h to reach the peak change in oxygenation compared 340 
to baseline and few had returned to baseline 1h after the patch was removed. The application of 341 
the different doses of GTN did not influence brain HbO2 concentrations (Fig4B).  342 
GTN has no effect on infarct volume and functional outcome after stroke  343 
None of the GTN doses influenced infarct volume at 24h (KW=2.53, p=0.639) (Fig5A), and 344 
neurological score outcomes were also comparable across all groups (KW=6.03, p=0.197) 345 
(Fig5B).  346 
Administration of 7.8µg/h of GTN increased NOx concentration in the plasma (F 4, 36 =4.327, 347 
p=0.005, post-hoc: 0 vs 7.8µg/h: p=0.025) (Fig5C). However, NOx levels in the brain were not 348 
altered by GTN administration (F4, 37 =0.5752, p=0.682) (Fig5D). An additional study was 349 
performed with patch administration at 0.2mg/h, which was also neutral (Supplemental Fig2&3).  350 
 351 
Discussion 352 
This study demonstrates that sub-dermal GTN modestly reduced MABP and prevented 353 
dangerous elevations in ICP, without impacting CPP, in a permanent ovine model of stroke. GTN 354 




vehicle group. However, the complementary rodent studies suggest that GTN appears to have 356 
no consistent effect on CBF and brain oxygenation, which is in line with clinical data, and was 357 
unable to influence outcome in a transient mouse model of stroke.  358 
A clinically relevant dose of GTN, provided at 2hrs post permanent MCAO in the ovine model via 359 
a subdermal patch that is used transdermally in humans, only marginally reduced MABP when 360 
compared to vehicle (approximately 10mmHg). Whilst this reduction was not significant, vehicle 361 
treated sheep with stroke exhibited significantly higher MABP than the sham surgery group. This 362 
suggests that GTN was able to slightly reduce MABP, a reduction that is within the range of 363 
systolic blood pressure reduction of 5-20 mmHg in clinical studies.3,4,6,10 The most interesting 364 
finding from this study is that GTN was extremely effective at preventing a rise in ICP without 365 
affecting CPP. While CPP was slightly higher in both vehicle and GTN-treated stroke groups 366 
compared to sham, there were no significant differences among any of the three groups. 367 
However, there was also no significant overall effect in CPP or CBF measurements in stroke 368 
patients treated with GTN.10, and on the contrary, some patients showed increased CBF in and 369 
around the infarcted region.10 While this study did not look at mechanisms by which GTN may be 370 
lowering ICP, it could be by directly combating cerebral oedema. There are many molecular 371 
mechanisms proposed to be involved in the formation of cerebral oedema in response to 372 
ischemia, such as increases in sodium influx and calcium signalling, break-down of blood-brain 373 
barrier (BBB) tight junctions, enzymatic activity and inflammation, reviewed by Simard et al.28 374 
Using the same ovine model of stroke, we have previously shown that blocking neurogenic 375 
inflammation with an NK1 tachykinin receptor antagonist was able to substantively decrease ICP 376 
and prevent BBB breakdown, potentially through the upregulation of transcellular mediator 377 
calveolin-1.14 BBB integrity is well known to be differentially mediated by NO depending on the 378 




detrimental, whereas endothelial NOS is considered beneficial, reviewed by Thiel & Audus.29. 380 
Vascular NO is reduced in stroke patients,30 and GTN may be acting via restoring this. Within our 381 
study the effect of GTN on blood pressure suggests endothelial availability, although more 382 
research could be done to understand cerebral absorption and biodistribution, particularly since 383 
we did not measure any brain NOx changes in mice across the wide range of doses. Although 384 
we observed a correlation between oedema and ICP, there might be additional mechanisms 385 
beyond oedema that have not been considered. Indeed, increases in ICP in rodent models of 386 
stroke have been reported that were not associated with oedema31,32 suggesting previously 387 
unknown mechanisms of ICP regulation that require additional investigation. One limitation of the 388 
ovine data is that there were unexpected facility changes that meant the GTN treated animals 389 
had to be maintained with pure oxygen rather than room air. This leads to significantly higher pO2 390 
levels in the GTN group compared to sham or vehicle. Breathing 100% oxygen (hyperoxia) is well 391 
established to cause cerebral vasoconstriction and subsequent reduction in CBF,33,34 albeit 392 
without impacting pressure autoregulation dynamics.35 Following a cerebral insult such as 393 
traumatic brain injury, hyperoxia also results in cerebral vasoconstriction36, along with significantly 394 
impaired pressure autoregulation.37,38 However, it is generally assumed that the increased 395 
oxygen-carrying capacity under hyperoxic conditions more than outweighs the small reduction in 396 
CBF. We cannot exclude that hyperoxia may have impacted our MABP results and potentially 397 
reduced CBF. However, given that CPP and pCO2 (a much more potent cerebral vasodilator) 398 
levels were preserved, this is unlikely. Indeed, in a recent ovine stroke study utilising 100% 399 
oxygen, no significant differences in the sham animals with respect to ICP or MABP were 400 
observed.15 A recent systematic review of the literature surrounding hyperbaric oxygen therapy 401 
in stroke suggested evidence from clinical trials is inconclusive with negative, positive and neutral 402 




While CBF was not directly measured in the ovine experiments, the murine results suggest that 404 
GTN did not influence CBF in a robust fashion. This is very similar to findings with intraarterial 405 
administration in the transient mouse MCAO,17 as well as in healthy volunteers treated with 406 
intravenous GTN in which global CBF remained unchanged along with internal carotid artery flow 407 
velocity, though there was a dose dependent decrease in flow velocity of the MCA.40 Stroke 408 
patients treated with GTN patches also exhibited reduced MCA flow velocity30 and another report 409 
indicated no effect of GTN on CBF in stroke patients.10 Despite no overall effect, high variability 410 
among patients was reported, and we observed the same in the mice. It could be that GTN has 411 
differential effects on CBF depending on differences in intra-individual absorption rates due to 412 
sub-cutaneous fat or even patch adhesion problems in the mice. There could also be potential 413 
issues with bioavailability. Indeed, plasma NOx levels were only noticeably higher than vehicle at 414 
the two highest doses (7.8 and 60µg/h) and even then, at 60µg/h, were too variable to achieve 415 
significance. However, when plasma NOx was measured in stroke patients treated with GTN at 416 
a range of doses (5-10mg), there was no change compared to control.30  417 
The results of the murine experiments also suggest that GTN was unable to reduce infarct size 418 
across a wide range of doses, nor provide functional benefit. This is in direct contrast to the study 419 
by Maniskas et al.17 in which a reduction in infarct volume was observed with the two highest 420 
doses of GTN (6-12µg/µL) along with reduced motor impairments in the rotarod. This study 421 
administered GTN intra-arterially, so it is possible that there are differences in distribution and 422 
metabolism of GTN between species, and a greater potency can be achieved via this route 423 
compared to sub-cutaneous absorption from our mini-pumps. A comparable rat study 424 
administered high dose (10mg) GTN intra-peritoneally before MCAO and also showed a reduction 425 
in infarct volume and reduced levels of anti-apoptotic Bcl-2 expression.16 This high dose could 426 




treatment window. In addition, in the Ovine studies Ketamine was required for anaesthetic, this 428 
may have had a synergistic interaction with GTN to improve CBF, improving the efficacy of the 429 
administered GTN. Timing of treatment across the studies is one factor that may account for the 430 
differing results. For our mouse studies we chose 20min post occlusion for GTN administration 431 
as this was the most acute timepoint possible within the range of the confines of the surgical 432 
procedure. Timing was a key consideration in the clinical studies, with early evidence indicating 433 
ambulance-based delivery within 2h of symptom onset was ideal.3 A subset of the ENOS patients 434 
treated early (within 6h) also showed improved recovery,5 but the RIGHT-2 patients treated within 435 
4h did not have a more favourable outcome.6   436 
Overall, it is difficult to compare absorption and bioavailability in rodents to large animals and 437 
humans, even though our plasma analysis in rodents is line with the clinical literature. The ovine 438 
model offered the advantage that the exact same patch available for humans could be used along 439 
with a comparable body mass, whereas the small body size of the rodent resulted in adherence 440 
issues that made mini-pumps preferable for recovery experiments. In addition to potential NO 441 
availability, the ovine model was also permanent, and it is feasible that GTN may be more 442 
beneficial in conditions of ongoing cerebral ischaemia. The transient model has a slightly delayed 443 
penumbra by comparison and can be accompanied by reperfusion injury in which GTN may be 444 
unable to offer benefit. The permanent model is also characterised by faster lesion evolution and 445 
greater cerebral oedema. An additional limitation is that neither model were aged or had co-446 
morbidities. 447 
 Together these results cannot indicate which model has greater translational relevance, but it 448 
does highlight the benefits of using multiple models to enhance translational work. Our results 449 
suggest that GTN’s ability to reduce ICP in the sheep might have implications for patients with 450 




decompressive craniectomy or osmotherapy.28 A greater understanding about the mechanisms 452 
of GTN action and its interaction with the pathophysiological time course of stroke may reveal 453 
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Figure Legends 599 
 600 
Figure 1. MABP, ICP and CPP over 24 hours following sham or MCAO surgery in sheep. 601 
Mean ± SD of MABP (A), ICP (B) and CPP (C) for all groups throughout the 24h monitoring period. 602 
*p<0.05, **p<0.01, vehicle cf. sham; †p<0.05, ††p<0.01 vehicle cf. GTN. Sham (n =4), GTN (n=7), 603 





Figure 2. MRI findings 24 hours post sham or MCAO surgery in sheep. 606 
There was no evidence of hyperintensity or tissue deformation in sham animals.  All stroke 607 
animals exhibited hyperintensity in T2 and DWI and lower ADC values (10-3 mm2/s). GTN (n=7), 608 





Figure 3. Infarct volume, oedema and the relationship to ICP in sheep. 611 
Mean ± SD of infarct volume (A), cerebral oedema (B) and midline shift (C) was all lower in the 612 
GTN compared to vehicle treated animals. (D) There was a strong positive relationship between 613 
cerebral oedema and infarct volume (r>0.5) and (E) cerebral oedema and midline shift (r>0.5). 614 






Figure 4. CBF and brain oxyhaemoglobin measurements with different doses of GTN in 618 
mice. 619 
A) Mean CBF in arbitrary units for 4 different doses of GTN: 0.69 (n=3), 3.12 (n=4), 12.5 (n=4) 620 
and 50µg/h (n=4). ICP CBF changes were normalised against baseline at time 0. GTN was 621 
administered for 60min, then removed and final measurements taken an additional 60min later 622 
(time: 120min). Data: median, max and min and interquartile range.  B) Mean oxyhaemoglobin 623 
concentrations for 4 different doses of GTN: 0.69 (n=3), 3.12 (n=3), 12.5 (n=3) and 50µg/h (n=3). 624 
GTN was administered for 60min, then removed and measurements taken an additional 30 and 625 
60min later (time: 90 and 120min). Data: median, max and min. 4 data points could not be 626 





Figure 5. Infarct volume, neurological score and NOx levels following GTN administration 629 
in mice. 630 
Median ± interquartile range of infarct volume (A) and of neurological score (B). (C) Plasma and 631 
(D) brain concentrations of NOx (Mean ± SD). 0 (n=9-10), 0.078 (n=3-7), 0.78 (n=9), 7.8 (n=12) 632 
and 60µg/h (n=7-8). For NOx levels 3 plasma and 2 brain samples were not of sufficient quality 633 
to obtain a reading and were excluded.  634 
 635 
